This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.

A number of single domain antibodies (sdAb, also known as nanobodies or VHH) were developed that bind nucleocapsid protein of the SARS-CoV-2 virus. They are useful for detecting the virus and could also find application in therapeutics.

Embodiments of the disclosure relate to the domain of virology of Paramyxoviruses. The disclosure concerns a method for producing self-assembling paramyxoviral particles and a method for identifying a compound able to inhibit the replication or the transcription of a Paramyxovirus. The disclosure also pertains to the nucleocapsid-like particles obtainable by the method of the invention and their use for biotechnological and pharmaceutical applications.

The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject. The invention also provides kits comprising the matched antibody pairs of the invention and methods for using the kits for immunoassays for the specific detection of one or more serotypes of dengue virus in a patient population. The present invention also provides monoclonal antibodies specific for the NS1 protein of dengue virus and therapeutic compositions and methods for treating dengue virus infection.

This technology relates in part to optical methods for analyzing particles, including nanoparticles, thereby determining their presence, identity, origin, size and/or number in a sample of interest.

The invention relates to a detection method using an inactivated SARS-CoV-2 virus for the detection of anti-SARS-CoV-2 antibodies in samples. The method includes incubating the biological sample with inactivated purified SARS-CoV-2 whole virus particles under suitable conditions to obtain a SARS-CoV-2 virus/antibody complex and detection of such complex.

Devices and associated methods for analyzing patient samples are disclosed herein. In some embodiments, a device includes a housing base configured to retain a test strip, and a housing cover configured to couple to the housing base to at least partially enclose the test strip. The housing cover can include a fluid reservoir configured to hold a solution for hydrating a sample swab. The housing can further include an aperture configured to permit transfer of a sample from the sample swab onto the test strip.

A method and apparatus for comfortably, rapidly, and inexpensively collecting a sample from one or more test subjects and analyzing it, singly or pooled with other samples, for presence of SARS-CoV-2. Saliva, nasal drainage, or other body fluids may be collected from one or more test subjects and examined by means of fluorimetry. Mass rapid screening for SARS-CoV-2 is a valuable public health tool to reduce the transmission of COVID-19 while permitting business activity to resume.

A sensor device is provided for detecting an incidence and/or a concentration and/or an amount of an analyte in a sample. The sensor device includes a sensor, connection electronics and a housing. The sensor converts chemical and/or biochemical information of an analyte in a sample into an electrical signal. The sensor includes a test cantilever that has a base and a deformable part, where a receptor layer for selective reception of the analyte is applied at least to the deformable part. The sensor also includes a reference cantilever that has a base and a deformable part, where a reference layer for selective non-reception of the analyte is applied to the deformable part.

The invention relates to multimers such as multimers comprising 4 copies of a binding site or peptide; tetramers of polypeptides; and tetramers, octamers, dodecamers and hexadecamers of epitopes or effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides. The invention also relates to methods and uses to expand antigen specificity of binding sites, as well as vaccines, methods of vaccination and assay methods and reagents.